78,460- Total liabilities276,028215,457 Equity: Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issued and outstanding-- Common stock, $0.001 par value; authorized: 100,000,000 shares; issued: 71,257,940 and 72,199,837 shares at March 31, 2012 and June 30, 2011, respectively; outstanding: 71,257,940 and 70,059,819 shares at March 31, 2012 and June 30, 2011, respectively
7170 Additional paid-in capital405,393373,963 Accumulated other comprehensive income
1,877127 Accumulated deficit(196,163)(144,385) Total stockholders' equity
211,178229,775 Noncontrolling interest
5,52310,552 Total equity
216,701240,327 Total liabilities and equity
Non-GAAP Financial MeasuresThis press release includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission, with respect to the three and nine months ended March 31, 2012. "GAAP" refers to generally accepted accounting principles in the United States.
Accuray closed the acquisition of TomoTherapy on June 10, 2011 and TomoTherapy's operations since that date are included in Accuray's consolidated results of operations. Accounting for the impact of this acquisition has resulted in changes to the value of assets and liabilities from the amounts reflected by TomoTherapy prior to the acquisition and the creation of incremental assets and liabilities including intangible assets for developed technology and backlog, and unfavorable lease obligations. These changes have impacted revenues and expenses recorded in Accuray's consolidated statements of operations since the close of the acquisition. In addition, Accuray has incurred significant expenses as a result of the acquisition, some of which are one-time charges while others are expected t
|SOURCE Accuray Incorporated|
Copyright©2010 PR Newswire.
All rights reserved